001065.KS
JW Pharmaceutical Corporation [001065.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
001065.KS Stock Summary
Top 10 Correlated Stocks
001065.KS
In the News
001065.KS Financial details
Company Rating
Strong Buy
Market Cap
764.84B
Income
37.83B
Revenue
701.39B
Book val./share
-
Cash/share
-
Dividend
388.35
Dividend %
1.23%
Employees
1.13K
Optionable
No
Shortable
Yes
Earnings
-
P/E
87.46
Forward P/E
-
PEG
-1.2
P/S
1.09
P/B
13.32
P/C
-
P/FCF
27.14
Quick Ratio
0.35
Current Ratio
1.08
Debt / Equity
1.13
LT Debt / Equity
0.12
-
-
EPS (TTM)
86.39
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
4.96%
Revenue Q/Q
-10.24%
EPS Q/Q
-
-
-
-
-
SMA20
-1.46%
SMA50
2.77%
SMA100
0.07%
Inst Own
-
Inst Trans
-
ROA
6%
ROE
17%
ROC
0.25%
Gross Margin
43%
Oper. Margin
10%
Profit Margin
5%
Payout
-
Shs Outstand
24.32M
Shs Float
13.9M
-
-
-
-
Target Price
-
52W Range
28900.0-38400.0
52W High
-18.1%
52W Low
+8.82%
RSI
39.84
Rel Volume
0.87
Avg Volume
261
Volume
228
Perf Week
-1.72%
Perf Month
-0.79%
Perf Quarter
-10.53%
Perf Half Y
-9.24%
-
-
-
-
Beta
0.252724
-
-
Volatility
231.23%, 343.29%
Prev Close
0.32%
Price
31450
Change
0.32%
001065.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 22.09K | 0 | 0 | 5.78K | 0 | |
| Net income per share | 331.3 | 0 | 0 | -13.74 | 0 | |
| Operating cash flow per share | 2.14K | 0 | 0 | 172.78 | 0 | |
| Free cash flow per share | 1.8K | 0 | 0 | 49.79 | 0 | |
| Cash per share | 1.27K | 0 | 0 | 625.99 | 0 | |
| Book value per share | 10.7K | 0 | 0 | 1.92K | 0 | |
| Tangible book value per share | 10.07K | 0 | 0 | 1.59K | 0 | |
| Share holders equity per share | 10.7K | 0 | 0 | 1.92K | 0 | |
| Interest debt per share | 7.56K | 0 | 0 | 2.41K | 0 | |
| Market cap | 579.95B | 0 | 0 | 3566.57B | 0 | |
| Enterprise value | 724.23B | 145.66B | 171.77B | 3778.34B | 175.64B | |
| P/E ratio | 71.98 | 0 | 0 | -2.47K | 0 | |
| Price to sales ratio | 1.08 | 0 | 0 | 5.88 | 0 | |
| POCF ratio | 11.13 | 0 | 0 | 196.79 | 0 | |
| PFCF ratio | 13.25 | 0 | 0 | 682.94 | 0 | |
| P/B Ratio | 2.23 | 0 | 0 | 17.73 | 0 | |
| PTB ratio | 2.23 | 0 | 0 | 17.73 | 0 | |
| EV to sales | 1.35 | 0.28 | 0.31 | 6.23 | 0.26 | |
| Enterprise value over EBITDA | 19.79 | -58.63 | 11.29 | 79.74 | 2.13 | |
| EV to operating cash flow | 13.9 | 2.62 | 2.72 | 208.47 | 3.09 | |
| EV to free cash flow | 16.55 | 3.43 | 3.58 | 723.49 | 3.95 | |
| Earnings yield | 0.01 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0.08 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0.67 | 0.82 | 0.88 | 1.22 | 0.87 | |
| Debt to assets | 0.3 | 0.33 | 0.33 | 0.39 | 0.33 | |
| Net debt to EBITDA | 3.94 | -58.63 | 11.29 | 4.47 | 2.13 | |
| Current ratio | 1.64 | 1.21 | 1.28 | 1.3 | 1.12 | |
| Interest coverage | 2.48 | -1.69 | -0.72 | 4.25 | 6.71 | |
| Income quality | 6.47 | -2.2 | -4.13 | -12.57 | 1.9 | |
| Dividend Yield | 0.01 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0.81 | -0.27 | -0.46 | -4.96 | 0.23 | |
| Sales general and administrative to revenue | 0.12 | 0.08 | 0.12 | 0.14 | 0.13 | |
| Research and developement to revenue | 0.04 | 0.05 | 0.04 | 0.03 | 0.05 | |
| Intangibles to total assets | 0.03 | 0.04 | 0.03 | 0.03 | 0.03 | |
| Capex to operating cash flow | -0.16 | -0.24 | -0.24 | -0.71 | -0.22 | |
| Capex to revenue | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 | |
| Capex to depreciation | -0.47 | -0.64 | -0.73 | -0.8 | -0.73 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 8.93K | 0 | 0 | 770.07 | 0 | |
| ROIC | 0.03 | -0.03 | -0.01 | 0 | 0.09 | |
| Return on tangible assets | 0.01 | -0.05 | -0.03 | 0 | 0.05 | |
| Graham Net | -10.36K | 0 | 0 | -3.12K | 0 | |
| Working capital | 145.54B | 57.07B | 64.58B | 83.77B | 45.33B | |
| Tangible asset value | 244.97B | 208.7B | 189.8B | 167.07B | 209.49B | |
| Net current asset value | 40.23B | -8.06B | -42.29B | -78.06B | 23.24B | |
| Invested capital | 0.67 | 0.82 | 0.88 | 1.22 | 0.87 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 52.03B | 44.78B | 46.49B | 49.76B | 67.28B | |
| Average inventory | 104B | 95.9B | 95.82B | 101.86B | 107.1B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 47.71 | 46.99 | 47.26 | 50.64 | 76.34 | |
| Days of inventory on hand | 108.78 | 94.26 | 99.88 | 100.54 | 102.82 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 7.65 | 7.77 | 7.72 | 7.21 | 4.78 | |
| Inventory turnover | 3.36 | 3.87 | 3.65 | 3.63 | 3.55 | |
| ROE | 0.03 | -0.11 | -0.07 | -0.01 | 0.13 | |
| Capex per share | -343.15 | 0 | 0 | -122.99 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 1.49K | 1.57K | 1.61K | 0 | 0 | |
| Net income per share | 91.09 | 9.34 | 78.8 | 0 | 0 | |
| Operating cash flow per share | 54.89 | 87.58 | 173.43 | 0 | 0 | |
| Free cash flow per share | 18.8 | 66.33 | 140.52 | 0 | 0 | |
| Cash per share | 659.84 | 662.59 | 1.39K | 0 | 0 | |
| Book value per share | 1.93K | 1.95K | 2.04K | 0 | 0 | |
| Tangible book value per share | 1.62K | 1.63K | 1.72K | 0 | 0 | |
| Share holders equity per share | 1.93K | 1.95K | 2.04K | 0 | 0 | |
| Interest debt per share | 2.42K | 2.34K | 2.22K | 0 | 0 | |
| Market cap | 3982.43B | 3824.6B | 3530B | 0 | 0 | |
| Enterprise value | 4201.06B | 4033.7B | 3725.91B | 175.64B | 257.86B | |
| P/E ratio | 103.88 | 973.45 | 106.44 | 0 | 0 | |
| Price to sales ratio | 25.47 | 23.18 | 20.78 | 0 | 0 | |
| POCF ratio | 689.53 | 415.05 | 193.45 | 0 | 0 | |
| PFCF ratio | 2.01K | 548.02 | 238.75 | 0 | 0 | |
| P/B Ratio | 19.58 | 18.66 | 16.48 | 0 | 0 | |
| PTB ratio | 19.58 | 18.66 | 16.48 | 0 | 0 | |
| EV to sales | 26.87 | 24.45 | 21.94 | 0.91 | 1.49 | |
| Enterprise value over EBITDA | 237.31 | 275.12 | 194.94 | 5.66 | 3.4 | |
| EV to operating cash flow | 727.39 | 437.74 | 204.19 | 7.47 | 1.04K | |
| EV to free cash flow | 2.12K | 577.98 | 252 | 8.5 | -18.09 | |
| Earnings yield | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 1.24 | 1.19 | 1.08 | 0.87 | 1.13 | |
| Debt to assets | 0.4 | 0.39 | 0.37 | 0.33 | 0.42 | |
| Net debt to EBITDA | 12.35 | 14.26 | 10.25 | 5.66 | 3.4 | |
| Current ratio | 1.46 | 1.52 | 1.22 | 1.12 | 1.08 | |
| Interest coverage | 5.64 | 3.39 | 4.42 | 17.57 | -37.06 | |
| Income quality | 0.61 | 10.83 | 2.24 | 2.06 | 0.02 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.14 | 0.14 | 0.13 | 0.12 | 0.32 | |
| Research and developement to revenue | 0.04 | 0.04 | 0.05 | 0.06 | 0.04 | |
| Intangibles to total assets | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Capex to operating cash flow | -0.66 | -0.24 | -0.19 | -0.12 | -58.29 | |
| Capex to revenue | -0.02 | -0.01 | -0.02 | -0.01 | -0.08 | |
| Capex to depreciation | -0.81 | -0.56 | -0.85 | -0.7 | -2.18 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.99K | 639.63 | 1.9K | 0 | 0 | |
| ROIC | 0.02 | 0 | 0.02 | 0.04 | 0.03 | |
| Return on tangible assets | 0.02 | 0 | 0.01 | 0.02 | 0.02 | |
| Graham Net | -3.06K | -2.92K | -2.1K | 0 | 0 | |
| Working capital | 117.4B | 124.64B | 74.31B | 45.33B | 31.14B | |
| Tangible asset value | 170.23B | 171.8B | 180.88B | 209.49B | 211.46B | |
| Net current asset value | -74.59B | -68.51B | -7.71B | 23.24B | -18.59B | |
| Invested capital | 1.24 | 1.19 | 1.08 | 0.87 | 1.13 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 53B | 56.49B | 57.04B | 69.19B | 71.26B | |
| Average inventory | 104.81B | 109.29B | 110.96B | 111.05B | 115.32B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 53.14 | 52.84 | 49.85 | 71.5 | 54.94 | |
| Days of inventory on hand | 104.7 | 100.51 | 99.24 | 96.3 | 109.68 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.69 | 1.7 | 1.81 | 1.26 | 1.64 | |
| Inventory turnover | 0.86 | 0.9 | 0.91 | 0.93 | 0.82 | |
| ROE | 0.05 | 0 | 0.04 | 0.05 | 0.06 | |
| Capex per share | -36.09 | -21.25 | -32.91 | 0 | 0 |
001065.KS Frequently Asked Questions
What is JW Pharmaceutical Corporation stock symbol ?
JW Pharmaceutical Corporation is a KR stock and trading under the symbol 001065.KS
What is JW Pharmaceutical Corporation stock quote today ?
JW Pharmaceutical Corporation stock price is $31450 today.
Is JW Pharmaceutical Corporation stock public?
Yes, JW Pharmaceutical Corporation is a publicly traded company.
Company Profile
- Volume Average 261
- Market Capitalization 764.84B
- Employee 1.13K
- CEO Mr. Young-Sub Shin
- Headquarters Seoul,KR
- IPO Date 2005-09-29
-
Website
https://www.jw-pharma.co.kr 
JW Pharmaceutical Corporation develops, manufactures, and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cardiovascular, gastrointestinal, urinary, oral hypoglycemic, antibiotics, anti-fungal, Ob and Gy, renal, CNS, anti-anemic, respiratory, rheumatic arthritis, anticancer, anesthetic, antidotes, amino acids, TPN, and others. The company was founded in 1945 and is headquartered in Seoul, South Korea.
